Search

Cryopreserved human iPSC-derived cortical neurons, glutamatergic or GABAergic, shipped by vial.

Cryopreserved human iPSC-derived spinal motor neurons, including ALS patient and isogenic control lines.

Expandable human iPSC-derived neural stem cells for customers who want to differentiate in-house.

Cryopreserved human iPSC-derived astrocytes for neuronal co-culture and glial studies.

Cryopreserved human iPSC-derived ventricular or atrial cardiomyocytes, spontaneously contractile after plating.

Myogenic progenitor cells for casting skeletal muscle tissue, from iPSC-derived catalog vials up to GMP-grade primary production.

Undifferentiated human induced pluripotent stem cell lines as a starting material for customer-run differentiation.

Cryopreserved human iPSC-derived microglia, including APOE and TREM2 disease backgrounds and CRISPR-ready lines.

Cryopreserved human iPSC-derived oligodendrocyte-like cells and oligodendrocyte precursor cells, from the one supplier that publishes a price.

Primary human endothelial cells, pooled or single-donor, with published passage and population-doubling guarantees.

Hepatocytes as cells rather than as a finished model, across primary, iPSC-derived and immortalised routes.

The two cell types every skin model is built from, with age grade and disease state selectable at order.

Matched mutant and corrected iPSC lines from the public banks, priced at both academic and commercial tiers.

The cheap vials that should carry protocol rehearsal, so the expensive human vials carry the experiment.

Living, metabolically active 3D human epidermal tissue on culture inserts, delivered on a weekly production cadence.

Living pseudostratified, ciliated human airway tissue cultured at an air-liquid interface.

Living human small intestine or colon epithelium in planar or crypt format for permeability, metabolism and barrier work.

Pre-formed 3D human liver spheroids delivered ready for dosing, on a published production schedule.

Microfluidic plates arriving with tissue already seeded and perfused, so the buyer never handles cells or ECM.

The four corneal models named in OECD TG 492, each with a different published pass mark and batch release range.

Buccal, gingival, oesophageal, bladder and vaginal epithelium from the two skin-model suppliers, almost all outside the guideline system.

Dermal-epidermal skin equivalents, and the only category in this market with a complete published price list.

Pre-formed endothelial tubules and angiogenic sprouting models, including the rare assay-ready plate with a public price.

Organoid models where the purchase and the permission are two separate transactions, and only one of them has a price.

Ready-to-use pseudostratified, ciliated, mucus-producing human airway epithelium on inserts, specified by anatomical region and donor pathology.

AT1/AT2 alveolar epithelium with surfactant secretion, available as a static insert tissue or as a perfused microphysiological system on an instrument.

Perfusable or insert-based human renal proximal tubule epithelium for transporter, permeability and nephrotoxicity work, assembled from publicly priced primary cells.

Pre-formed 3D human cardiac microtissues delivered ready for dosing, for contractility, structural and metabolic cardiotoxicity endpoints without an anchored geometry.

Multicellular tumour spheroids and 3D cancer constructs, where the plasticware and the cell lines are publicly priced and the finished model is not.

Perfusable human brain endothelial tubules and static BBB co-cultures for permeability, transporter and CNS penetration work, with one route carrying a live public price.

Aligned, mechanically anchored, electrically stimulable engineered skeletal muscle tissue built and force-tested against a written specification.

Motor neurons and myotubes co-cultured in a compartmentalised device so that neural stimulation drives muscle contraction.

Finished human engineered myocardium from iPSC-derived cardiomyocytes and fibroblasts, shipped living at ambient temperature with a certificate of analysis, at a published per-tissue price.

Cardiomyocytes cast between two flexible posts or stretchers so that contraction deflects a known geometry and force becomes measurable, sold as plate plus cells rather than as finished tissue.

Engineered muscle carrying a channelrhodopsin so that contraction is triggered by patterned light rather than a field electrode, giving spatial addressing no electrode pair can provide.

Human neurons plated onto multi-electrode arrays, matured to spontaneous network activity, and delivered as a live recording-ready culture.

Human iPSC-derived cortical neurons plated with glia onto a multielectrode array and matured to recordable network activity, costed from a published academic core rate card.

A 3D neural organoid coupled to an electrode array so that network activity inside the tissue, not just at its base, becomes recordable.

Neuronal or cardiac cultures plated onto CMOS high-density arrays giving thousands of bidirectional electrodes per well, for single-cell-resolution network structure rather than well-average activity.

Ground-up design, prototyping and cleanroom production of custom PDMS culture devices, from single prototypes to batch runs.

Off-the-shelf micropillar casting devices in which the customer forms their own anchored 3D muscle tissue.

Electrical pacing lids and contractile-force measurement instruments for maturing and phenotyping engineered tissue.

MEA consumables sourced to your platform, Axion CytoView multiwell plates, Multi Channel Systems glass arrays, MaxWell HD-MEA plates, with the recurring cost stated before you commit.

Microwell and ultra-low-attachment plates for aggregate formation, InSphero Akura and Gri3D at published prices, plus the bulk formats that are quote-only.

Permeable membrane inserts specified by material, pore size and pore density rather than by catalogue habit, with published growth areas so your TEER and permeability numbers normalise correctly.

Pressure-driven pumps, fluidic units and channel slides for defined shear stress, with the published coefficients that tell you what your flow rate actually means.

Perfusable chip plates sourced on a per-chip basis, AIM Biotech idenTx and organiX at published list prices, MIMETAS OrganoPlate and Emulate chip kits against derived procurement anchors.

Soft-lithography fabrication broken into the two numbers every quote contains, one-time tooling and per-part cost, using the handful of fabricators that publish a rate card.

Resin-printed chambers, manifolds, holders and casting moulds for fast iteration, specified around the two ways printing actually fails.

Tendon, ligament, cartilage and other animal tissues collected, processed and shipped to a written customer specification.

Consented human tissue, adipose, biofluids and disease-state specimens sourced from banked inventory or collected prospectively.

PBMCs, leukopaks and isolated immune subsets from apheresis donors, including recallable donor programmes.

Several cell types, tissues and nucleic acids from the same individual, ordered as a set rather than assembled by luck.

Outsourced expansion of your cells to a target cell number, cryopreserved into a documented bank at research or GMP grade.

Outsourced directed differentiation of iPSCs or progenitors into a specified mature cell type, delivered as cells or as a formed tissue.

Contract reprogramming of fibroblasts, PBMCs or renal epithelial cells into clonal iPSC lines with banked vials and identity testing, one of the few contract services with published prices.

Banking a line you already have, expand, freeze, test and store, at published institutional rates, priced per vial rather than per programme.

Cells delivered plated, or a single-lot bank aliquoted for a whole campaign, separating the three different products sold under one phrase.

Independent release testing of cells or tissue against compendial methods before you accept delivery.

Sectioning, staining, multiplexed immunofluorescence, 3D imaging and quantitative image analysis of delivered tissue.

Functional acceptance testing of engineered tissue, twitch and tetanic force, fatigue, damage, and electrophysiological activity.

Independent cell line authentication by STR profiling and G-band karyotype, at published rates, with the loci and database comparison specified rather than assumed.

Contamination and compendial release testing at published rates, with the method stated, because two assays with the same name are not the same test.

Buy the recording rather than the platform, MEA recordings and high-content imaging at a published per-recording rate card, with no instrument purchase.

Packaging, documentation and time-critical shipping of live tissue on cold packs or frozen material on dry ice or in vapour-phase nitrogen.

Liquid nitrogen vapour shippers rented at published monthly rates, charged and data-logged, for material that cannot travel on dry ice.

Every verified public price on this site in one table, with the source and the date observed for each. Cells, tissue, plates, chips, QC, banking, devices, shipping and core-facility rates, plus an honest register of what is quote-only and why.

The published two- and three-tier pricing structures in the engineered living components market, Coriell, Addgene, MD Anderson, Salk, Boston Children's, Baylor, Arizona Genetics Core, with the measured multipliers, who qualifies for each tier, and what the cheap tier does not include.

A transparent total-cost-of-ownership model for making iPSC-derived neurons in-house versus buying them: reagents, media, line licence, technician hours, facility charge, failure rate and QC, against catalogue price, with breakeven by batches per year. Every unit price is sourced and dated.

A specification and price comparison of reconstructed human epidermis models, MatTek EpiDerm, EPISKIN SkinEthic RHE, Phenion FT and others, with OECD validation status, kit format, shipping cadence and shelf life, and which suppliers publish a price.

A transparent model of what a failed differentiation costs in cells, consumables, labour, instrument time and schedule, with every unit price sourced and dated, every assumption stated, and the arithmetic shown in full. Explicitly a model, not a quotation.

Instrument, consumable and per-well economics for organ-on-chip platforms, Emulate, MIMETAS, CN Bio, AIM Biotech and InSphero, built from live storefront prices where they exist and from federal procurement records with stated quantities where they do not.

Published list prices for human iPSC-derived astrocytes, microglia, oligodendrocytes and OPCs, plus rodent astrocytes, normalised per million cells across iXCells, Axol, bit.bio and FUJIFILM CDI, with the media costs that come attached and the SKUs that are quote-only.

What master cell banks, working cell banks and research-use banks cost, what testing is bundled into each, and where the published prices stop and the quote-only wall begins. Sourced and dated figures from named providers and published institutional rate cards.

Published prices for cell line authentication (STR), mycoplasma detection, sterility, karyotyping and endotoxin testing, by assay, method, provider, price and turnaround, with a note on when each test becomes required rather than optional.

Published fabrication pricing for custom microfluidic and culture devices, split into non-recurring tooling and per-part cost, by method (soft lithography, injection moulding, laser, 3D printing) across volume tiers of 1, 10, 100 and 1,000 parts. Every figure sourced and dated.

Published list prices for human iPSC-derived cardiomyocytes from Axol Bioscience, BPS Bioscience and FUJIFILM Cellular Dynamics, normalised per million cells, with purity specifications and the source and date for every figure.

Published list prices for human iPSC-derived neurons, normalised to cost per million cells, across named suppliers. Recorded from supplier sources with the date and URL for each figure.

Published carrier dangerous-goods surcharges, dry shipper rental rates, supplier handling fees and repository shipping charges for cells and tissue, with what actually drives the number: temperature class, destination, permits and the value of what is inside the box.

No multielectrode array vendor publishes plate pricing. This page derives per-plate costs from US federal procurement records with stated quantities, a published European order confirmation, and live storefront prices for adjacent consumables, with the per-well and per-experiment arithmetic.

What Wetware World brokers, how long each category actually takes, and which categories have a catalogue price versus which require an RFQ. A category matrix built from verified supplier data.

eNUVIO OMEGA-MP is USD $440.00 for four devices and eight experiments, the only public price in the category. This compares it against OMEGA96-MP, the Curi Bio Mantarray plate kits and custom PDMS posts on well count, post stiffness, force readout and tissue volume.

A sourcing guide to ready-to-use human liver microtissues and spheroids, InSphero 3D InSight, MatTek HUREL micro livers, CN Bio PhysioMimix liver plates and others, with donor pooling, longevity in culture, published per-plate prices, production schedules and shipping arrangements.

A buying guide for reconstructed human epidermis, which models hold OECD TG 439 and TG 431 validation, what a kit contains, verified shipping cadence and shelf life, QC-on-arrival procedure, and the one supplier that publishes a full price list.

A sourcing guide for human vascular endothelial cells, HUVEC and microvascular, covering published passage at ship, population doubling guarantees, the pre-screening premium, pooled versus single-donor lots, named pathogen panels and the SKU pair that shows what a cell price actually buys.

A sourcing guide to engineered heart tissue, myriamed myrPlate and myrTissue-Cardio with published prices, Curi Bio Mantarray, Ncardia and DiNABIOS (formerly EHT Technologies), covering format, force readout, instrument lock-in, lead time and what each route actually commits you to.

One supplier, myriamed, sells finished engineered skeletal muscle off a public storefront at EUR 1,400 per tissue. It publishes no force specification. This page names that option, the casting devices you can cast your own in, who will quote a custom programme, and the real published force numbers so you can judge a spec.

A sourcing guide for human dermal fibroblasts and keratinocytes, published prices from the one complete public price list in reconstructed tissue, why adult, neonatal and fetal grades are not interchangeable, matched-donor pairs for skin models, and the volume discount structure nobody uses.

A sourcing guide for human hepatocytes as cells rather than as a finished model, the three supply routes, the one published price, why a perfused liver plate consumes millions of unpriced primary cells, and the metabolic specifications to demand at release.

A sourcing guide for consented human tissue, adipose, biofluids and disease-state specimens, banked inventory versus prospective collection, the regulatory posture a serious supplier holds, why almost nothing is publicly priced, and the consent question that decides whether your project is publishable or commercialisable.

An availability table for human iPSC-derived cortical neurons across named suppliers, subtype, published purity specification, markers, format, lead time, licence class and price band, each traced to the supplier source it came from.

A supplier table for human skeletal myoblasts and muscle-derived cells covering donor disclosure, passage at ship, purity marker and threshold, whether fusion index is reported, price and lot variability, and what no supplier specifies.

Prices and specifications for human iPSC-derived astrocytes, microglia, oligodendrocytes and OPCs across named suppliers, plus the neuron-to-astrocyte co-culture ratios and seeding densities used in published multielectrode array work, with citations.

A sourcing table for human iPSC-derived cardiomyocytes across named suppliers, ventricular, atrial and nodal subtype availability, published purity specifications, beating and assay-ready timing, MEA and calcium-imaging validation, and list prices with the source and date for every figure.

A sourcing guide for human iPSC-derived microglia across the suppliers that publish list prices, pack economics, the flat disease-line uplift, engineered backgrounds priced at wild type, and why the matched medium is a specification rather than an accessory.

Published list prices for human iPSC-derived spinal motor neurons from iXCells, bit.bio, Axol and others, normalised per million cells, with the marker evidence each supplier publishes, the differentiation route where disclosed, and disease and isogenic line pricing.

A sourcing guide for matched mutant and corrected iPSC lines from the public banks, both published fee tiers at Coriell, RIKEN and EBiSC, the separately charged licence line item, what a two-tier price does and does not grant, and the specification checklist for an isogenic pair.

A sourcing guide for PBMCs, leukopaks and isolated immune subsets from apheresis donors, the three supplier models and what actually separates them, recallable donor programmes for longitudinal design, why the pre-analytical window decides between inventory and prospective collection, and the specification checklist for a cohort quote.

A compatibility matrix of iPSC neuron products against Axion Maestro, MaxWell MaxTwo and Multi Channel Systems MEA platforms, plate formats, electrode counts, seeding densities, days to bursting and co-culture requirements, and why "MEA-ready" carries no agreed definition.

A sourcing guide for human iPSC-derived neural stem cells and neural progenitors, published prices across two suppliers, the disease-line premium, what expandability is actually worth against buying differentiated neurons, and the donor consent restriction that propagates silently to derived products.

A sourcing guide for human iPSC-derived oligodendrocyte-like cells and OPCs, the single published price in the category, the lineage premium against astrocytes and microglia, why maturation duration dominates the true cost, and what to ask when there is no second quote.

A sourcing guide for rodent and immortalised cell lines used to qualify protocols before human material is committed, published prices against their human equivalents, where the substitution is legitimate, where published work says it is not, and why regional variants leave the catalogue entirely.

A comparison matrix of 3D skeletal muscle models, Curi Bio Mantarray, eNUVIO OMEGA-MP, Duke myobundles, myriamed myrPlate and myrTissue-Skeletal, and CYTOO MyoScreen, on cell source, device, force readout, maturation time, throughput and cost per data point, with published force figures.

A comparison of fourteen 3D tissue model suppliers, MatTek, EPISKIN, InSphero, MIMETAS, Emulate, CN Bio, TissUse, Altis, Visikol, Xellar, Phenion, J-TEC, myriamed and eNUVIO, on tissue types, format, whether they ship finished tissue or an empty device, custom capability and published price band.

A head-to-head of cell banking providers, WiCell, Cook MyoSite, uBriGene, Curi Bio and named institutional cores, on published price, what is included in the release panel, grade, turnaround, deposit-for-distribution options and who owns the resulting bank.

A head-to-head of contract iPSC differentiation providers, Curi Bio, Ncardia, Axol, bit.bio, Cook MyoSite, eNUVIO and FUJIFILM CDI, on lineages, whose line they will work on, published acceptance criteria, timelines, engagement models and the question that decides the purchase: whether the deliverable is cells or a report.

A head-to-head of the validated reconstructed human epidermis models, barrier function and ET-50 acceptance ranges, protocol parameters, OECD TG 439 and TG 431 validation status, formats, lead time and what is actually published about price.

An even-handed head-to-head of human iPSC-derived astrocyte suppliers, price per million, published functional evidence, co-culture protocol support, disease panels, isogenic partners and licence posture, with the co-culture ratio the literature actually used and a note on where primary astrocytes still win.

A head-to-head of the main human iPSC-derived neuron suppliers, price per million, purity specification, subtype breadth, line provenance, published electrophysiology, licensing and minimum order, with a clear statement of where each one is strongest.

A head-to-head of human liver model suppliers, InSphero 3D InSight, MatTek HUREL micro livers, CN Bio PhysioMimix perfused plates, HepaRG and bit.bio ioHepatocytes, on model architecture, donor pooling, longevity, format, published price and what each route actually costs per data point.

A head-to-head of the five multielectrode array platform families, Axion Maestro, MaxWell MaxOne and MaxTwo, Multi Channel Systems, 3Brain CorePlate and Alpha MED MED64, on electrodes per well, simultaneous recording channels, plate reuse, published cell-product protocol support and the per-well economics no vendor will publish.

A head-to-head of named microfluidic fabricators, HiComp, Parallel Fluidics, eNUVIO, FlowJEM, Blue BioDevice, uFluidix, microfluidic ChipShop, Potomac Photonics, ALine and an academic cleanroom, on fabrication method, material, minimum feature size, published tolerances, minimum order quantity, non-recurring engineering cost and who keeps the tooling.

Eight organ-on-chip platforms against throughput, perfusion mechanism, membrane versus scaffold-free architecture, imaging compatibility, open versus closed consumables and published tissue models. No vendor publishes consumable pricing, that column is honestly empty.

Three culture architectures compared on physiological relevance, cost per data point, throughput and hands-on time, including an explicit account of when a Transwell insert is the right and cheaper answer, which is more often than the field admits.

A head-to-head of the three routes to human myogenic progenitors, primary from Cook MyoSite, PromoCell and Lonza, iPSC-derived from iXCells, bit.bio and myriamed, and immortalised lines, on price per million, purity marker, passage window, donor authenticity, disease panels and what each route costs you scientifically.

A service taxonomy for cell and tissue work: what each service is priced on, how long it takes, and the specific conditions under which outsourcing beats doing it in-house. Includes the three cases where in-house is clearly correct.

Who supplies cells already in the plate, in which formats, live or frozen, and how to work out whether the premium beats your own technician hours. An under-served niche with a genuinely narrow set of cases where it is the right purchase.

For anything that must stay below minus 150 C, dry ice is not sufficient and a liquid nitrogen vapour shipper is required. Unlike most of cold chain, these are rented at published rates, and the published rates say three things buyers consistently get wrong.

One institutional core publishes a full rate card for MEA recordings, imaging and project planning. Set that against a six-figure instrument, a five-figure service contract and a seven-week maturation, and below about one plate a month the arithmetic is not close.

Published rates for contamination and compendial release testing, with the method stated for each, and the line item that produces a first invoice several times the budget: method validation, charged once per matrix and invisible on every per-sample price list.

Banking a line you already own is priced per vial at institutional cores and per programme at commercial providers, and the two are priced on different bases. This is the published arithmetic, the three bank types, and why karyotype is half the release panel.

The same nominal STR assay ranges four-fold across published rate cards, and the cheap end is frequently a rate you cannot access. This is what separates the providers, loci count, database comparison, signed interpretation, and when karyotype stops being optional.

Who will culture, expand, differentiate, bank or plate cells for you, at what scale, under RUO or GMP, and on what price basis. Cook MyoSite runs a 3,470 sq ft ISO 7 / ISO 5 cleanroom for muscle cell manufacture; almost nobody publishes a rate.

Seven providers of contract iPSC differentiation compared on lineages offered, whether they will work on your line or insist on theirs, QC deliverables, published timelines and price basis. Includes the only published phase durations in the category.

Which fabrication method suits your feature size, what each fabricator will and will not take on, and the twelve-item specification checklist that makes two microfluidic quotes comparable instead of merely different.

Ten organ-on-chip providers mapped against platform lock-in, tissue types supported, perfusion mechanism, imaging compatibility, whether they sell a product or a service, and the engagement model each will actually sign. Plus the scoping questions that decide the price.

Seven providers of contract primary cell isolation compared on tissue types, donor sourcing and consent posture, yield expectations and price basis. Includes what a defensible consent chain looks like and why nobody guarantees yield.

A PDMS device quote has six cost centres, master, casting, bonding, surface treatment, sterilisation and QC. Most first-round quotes price two of them. This page shows the full anatomy and a comparable quote structure you can send to any shop.

Fourteen organisations that will quote tissue engineering work, mapped against scaffold, bioprint, muscle, skin, vascular and organ-on-chip capability, regulatory scope, instrumentation and engagement size, including which parts of this market have closed down.

Three routes to a culture device: buy off the shelf, modify something that exists, or fabricate from scratch. This page sets out what each route costs, how long it takes, and the questions that decide which one you are actually on.

Commercial resin printers resolve at 50 µm pixels, not at microfluidic scale, research printers reach 18 µm and below. This sets out the resolution ceiling, the resin cytotoxicity problem, the published biocompatibility data and when printing beats moulding.

Printing a culture device is faster than moulding one and fails in two ways soft lithography does not: the resolution is worse than the pixel size implies, and the resin can be cytotoxic. This is how to scope, specify and accept a printed prototype without losing a batch of cells to it.

Every multielectrode array vendor publishes a complete electrode specification and no price. This is the buying guide: what separates Axion, Multi Channel Systems, MaxWell, 3Brain and Alpha MED, the derived transaction prices we could evidence, and the commercial terms that decide the three-year bill.

AIM Biotech publishes a full price list; MIMETAS, Emulate and CN Bio publish none. This is the per-chip arithmetic across platforms, the derived procurement anchors with their caveats stated, and why chip material is a scoping decision rather than a detail.

A rocker and a pressure controller are not two price points for the same thing. This is the procurement guide to perfusion hardware, ibidi list prices verified 2026-09-01, the published shear coefficients that vary fifteen-fold across one product family, and the specification line that stops you reporting a shear stress your cells never saw.

A handful of fabricators publish rate cards, which makes soft lithography one of the few custom processes you can cost before opening a sales conversation. This is that arithmetic, published NRE and per-part figures, the amortisation curve, and the single RFQ line most buyers omit.

A rocker costs nothing per channel and gives you bidirectional gravity flow. A pressure-driven pump costs five figures and gives you a defined shear stress. This sets out the four perfusion routes, their published shear stress relationships and the live-verified prices.

The ANSI/SLAS microplate standards give five numbers a custom culture device must respect to work with the imager, the liquid handler and the plate reader you already own. This is what each one is, where the tolerance sits, and which failures are recoverable.

AggreWell, Sphericalplate 5D, Corning Elplasia, InSphero Akura and Gri3D produce between one and 12,000 spheroids per vessel. This compares published microwell counts, cell loading ranges and materials, with the live-verified list prices where they exist.

Autoclaving is free and deforms thermoplastics. Gamma is a service and changes polymer crosslinking. EO leaves residuals with published limits. This sets out the five sterilisation routes against material compatibility, surface treatment survival and what to write into a device specification.

Plasma treatment turns PDMS hydrophilic and it starts reverting within minutes. This sets out the published contact-angle data, the storage protocols that extend the window, the ECM coating options, and what to write into a device specification so the surface arrives usable.

Corning publishes growth areas, pore densities and membrane characteristics for every Transwell format. This is that data assembled, plus why a TEER value measured with chopstick electrodes is not comparable to one measured any other way.

An availability map of engineered human tissue by type, which are shipped as off-the-shelf living products, which are custom programmes, and which exist only in academic laboratories, with the supplier count and the evidence behind each classification.

The alveolus splits into a finished static insert tissue and a perfused chip you seed yourself. Neither route publishes a price. This page sets out what each one actually delivers, the two-week stability statement that ends most repeat-dose studies, and the only instrument figures that exist, which are derived from federal awards and are upper bounds.

The self-assembly BBB route is priced end to end on a public storefront, down to the supplement and the per-chip cost. The prepared perfused route removes the seeding skill requirement entirely and publishes no price at all. This page sets out both, checks the bundle arithmetic, and names the field that should decide between them.

A sourcing guide to off-the-shelf human airway tissue, MatTek EpiAirway, EpiNasal and EpiAlveolar, Epithelix MucilAir, SmallAir and AlveolAir, with verified TEER release criteria, culture longevity, donor disease panels, anatomical region mapping and the post-shipment QC problem nobody mentions.

A sourcing guide to reconstructed human cornea-like epithelium, EpiOcular, SkinEthic HCE, LabCyte CORNEA-MODEL24 and MCTT HCE, with the OECD TG 492 prediction model cut-offs, published QC batch release ranges, exposure protocols and what the guideline says these models cannot do.

A sourcing guide to human intestinal tissue models, Altis RepliGut Planar and Crypt, MatTek EpiIntestinal, MIMETAS OrganoReady Colon and CN Bio gut plates, covering regional identity, the planar-versus-organoid geometry decision, published Caco-2 comparisons, time to a working barrier and what to specify in a quote.

A sourcing guide to human mucosal tissue models, MatTek EpiOral, EpiGingival and EpiVaginal, EPISKIN SkinEthic HGE, HO2E, HBE and HVE, covering non-keratinised versus keratinised mucosa, why most of this category sits outside OECD validation, and what to specify when there is no acceptance criterion to point at.

Scaffold-free cardiac microtissues answer beat rate, calcium handling and viability questions and cannot answer absolute force questions. This page sets out the geometry decision that must be made before any money moves, the publicly priced self-forming route, and why no supplier surveyed publishes a price for a finished cardiac microtissue.

Human renal proximal tubular epithelial cells carry live list prices at two suppliers and perfused culture plates carry live list prices at a third. No supplier surveyed sells a released, barrier-verified proximal tubule model against a TEER or transporter acceptance criterion. This page prices the parts and states plainly what the assembly costs you in risk.

The practical difference between self-organising organoids and engineered tissue constructs, apical access, assay compatibility, batch variability, Matrigel dependence and the oxygen diffusion limit, and how the choice determines which suppliers and which assays are available to you.

Living tissue is manufactured to a calendar, not held in inventory. The published shipping cadences, order-by dates, shelf lives and post-shipment QC windows from MatTek, Epithelix and InSphero, and how to plan a study around a supply that does not exist until it is made.

Cancer cell lines at $577.00, spheroid microplates at $59.75, ECM-patterned chips at $7.60 per experiment, and no supplier selling a released plate of size-specified, viability-verified spheroids. This page prices the self-assembly route and explains why microwell diameter is the decision that determines whether your model works at all.

Engineered tissue stops at roughly 100–200 µm without a blood supply. What that physical limit means commercially, what vascular models actually ship today, what the bioprinting literature has demonstrated, and how to specify a thick-tissue project honestly.

A landscape map of biohybrid actuator work, which groups build what, from which cell source, with what published force, and the honest supply-side answer: finished contractile tissue is purchasable from one supplier at EUR 1,400, but nobody sells it against a force specification, so every project is still an integration job.

A complete parts list for one engineered muscle actuator, from cells to force readout, with a published price where one exists and an explicit "quote only" where it does not. Verified prices: eNUVIO $440, ATCC $577, myriamed EUR 1,400.

The commercial and academic landscape for neurons-as-compute: Cortical Labs CL1 and Cortical Cloud, FinalSpark Neuroplatform, and the general-purpose HD-MEA route. Substrate, electrode counts, access model and published prices, with sources and dates.

Cardiac muscle contracts by itself and never stops. Skeletal muscle does nothing until you tell it to, then does exactly that. Published forces, control models, lifetimes and commercial supply for both, with a citation on every claim.

What an engineering group must acquire, learn and staff before it can make a living actuator, and the one verified price that finally makes the make-versus-buy comparison answerable: myriamed lists a finished skeletal muscle tissue at EUR 1,400.

Published twitch and tetanic forces for engineered skeletal muscle, normalised to specific force in mN/mm² alongside cross-sectional area and stimulation protocol, with a citation on every row. The reference table for anyone writing a force specification.

Four cell sourcing routes for a biohybrid muscle actuator compared on cost, maturation time, published force, culture burden, approval burden and who will actually supply them. C2C12 is the default and it is a mouse cell line.

Putting motor neurons in command of engineered muscle adds a biological control layer to a biohybrid device. What the published work achieved, how the curare test proves a junction is real, and what you have to buy to attempt it.

Light-driven muscle actuation buys spatial addressing that electrodes cannot give, at the cost of a genetic modification step. Published forces, the 84 percent figure against electrical stimulation, and the four things you must actually acquire.

Living actuators run at 37 °C in buffered media inside a sterile incubator, and published untethered lifetimes are measured in days. The environmental constraints, the one documented ambient exception, and what that means for device design.

An end-to-end procurement flow for engineered living components, from specification through supplier selection, licensing, QC, shipping and acceptance, with a checklist for each of the eight stages.

A problem-first route to a working BBB model: the four buildable routes and what each measures, honest TEER targets and why the literature spans four orders of magnitude, the cell identity controversy you must know before choosing a protocol, published prices where they exist, a MODELLED insert-based budget, and a specification checklist.

A problem-first route to a working microelectrode array neurotoxicity assay: what the published EPA screening campaigns actually measured, the cells and plates you need with real prices, the buy-versus-outsource instrument decision, a MODELLED bill of materials for 24- and 48-well pilots, and a specification checklist.

What research-use cell line terms actually permit, quoted from published ATCC, EBiSC, Coriell and bit.bio agreements. The right to sell a differentiated derivative is almost never included in the purchase price.

A 15-item quality control checklist for buying cells: what each item is, why it matters, what an acceptable specification looks like, the red flag to watch for, and whether suppliers provide it as standard.

PDMS absorbs hydrophobic small molecules badly enough to invalidate pharmacology. This is the material matrix, absorption, optical clarity, gas permeability, autofluorescence, bondability, scalability and cost per part, with the published absorption data laid out properly.

A normalisation worksheet for custom biology quotes: the twelve line items that must be present, the terms that decide who pays for a failed batch, and two worked examples, quotes that look different and are identical, and quotes that look identical and are not.

Published plate formats and electrode counts for Axion Maestro, MaxWell MaxOne and MaxTwo, Multi Channel Systems, 3Brain CorePlate and Alpha MED Scientific MED64, with coating requirements and which cell products have published protocols on each.

The requirements a reconstructed human epidermis model must meet under OECD Test Guideline 439, tissue construction, barrier function expressed as ET-50 or IC50, the MTT viability assay, controls, run acceptance criteria and the prediction model, plus which commercial models hold validation and how TG 431 relates.

Observed lead times across 26 offerings, catalogue cells, living tissue models, engineered tissue, custom microfabrication, contract culture and QC, with what actually drives the variance and why a six-week quote becomes eleven weeks.

A problem-first sourcing route out of the rabbit skin test: which guideline answers which question, how many tissues a run actually consumes, what is purchasable and at what published price, the weekly production cadence that sets your schedule, and a specification checklist for an RhE quote.

A problem-first sourcing route for a cardiac safety screen: which readout answers your question, which cardiomyocyte SKUs have published prices, a modelled bill of materials for a 48-well MEA pilot and a 96-well plate, a week-by-week timeline, and a specification you can send to suppliers.

What actually breaks when a working 6-well experiment becomes a 384-well screen: the growth-area disagreement that changes your cell order by 50 percent, the volume tiers that decide the budget, edge effects, lot boundaries, plate lead times, a MODELLED cost comparison across formats, and a re-quote checklist.

A problem-first route to a working hepatic toxicity capability: which of the four liver model routes answers your question, the only published per-microtissue price in the category, a staged budget that defers the expensive decision, realistic timelines, and a specification checklist.

The four shipment formats for living material compared on viability risk, cost, customs and IATA treatment, and what to test on arrival. Includes the verified MatTek cold-chain model: 4°C on agarose gels, fixed weekly cadence, four-day shelf life including transit.

A triage method for buying living material against a fixed date: the four hard constraints no budget can shorten, the six soft ones you can attack, what is achievable at four, eight, twelve and twenty-six weeks, decision tables by material class, and the escalation language that actually works.

Reference tables of published growth areas per well for 6 to 384-well plates and MEA formats, sourced seeding densities for neurons and cardiomyocytes, cells per well, wells per one-million-cell vial, and a worked 48-well MEA calculation with honest correction factors.

A problem-first route for a laboratory with no iPSC experience: the buy-differentiated-versus-differentiate-yourself decision, line and repository choice with published fees, the QC panel and what it costs, a MODELLED first-experiment budget, a realistic timeline, and the specification to send.

Every organisation we hold evidence for across cells, tissue models, contractile tissue, culture devices, native tissue, contract manufacturing, QC and cold chain, with what each actually supplies, its region, whether it publishes a catalogue price, its RUO or GMP posture, and how strong our evidence is. Including the ones that have exited.

A directory of 3D bioprinter and bioink suppliers covering extrusion, light-based and volumetric platforms, with published consumable prices, which vendors gate instrument pricing behind a quote, and a dated record of the exits, including the Allevi end-of-service-life date that has already passed.

A directory of human and animal biospecimen suppliers, marketplaces, biorepositories, direct-to-patient collectors and animal tissue catalogues, covering prospective versus inventory collection, contracting structure, specimen classes, published prices and which vendors block verification.

A directory of extracellular matrix and hydrogel suppliers for 3D culture, basement membrane extracts, animal and human collagens, GelMA and photo-crosslinkable inks, and fully defined synthetic systems, with species of origin, whether stiffness is a specified parameter, and published prices.

A directory of human iPSC line sources, WiCell, Coriell, RIKEN BRC, EBiSC, ATCC and the commercial banks, with distribution fees at both academic and commercial tiers, the agreement each requires, who owns the underlying reprogramming patents, and what each will not let you do with a derivative.

A directory of named human iPSC-derived neuron suppliers with the columns that actually matter, subtypes offered, published purity, whether MEA data is published, line provenance, licensing posture, minimum order, lead time, region, RUO/GMP status and price band.

A directory of organoid model suppliers, biobanks and expansion services, adult stem cell versus iPSC-derived routes, tissue coverage, whether models are sold or only screened against, and the HUB technology licence that separates academic purchase from commercial use.

A directory of named primary human cell suppliers with the columns that decide whether a lot is usable, passage at ship, guaranteed population doublings, the pathogen panel, donor disclosure, delivery format and published price, with the source and date for every figure.

An A–Z reference of terms used in buying and specifying engineered living components: cells, engineered tissue, culture devices and the QC, licensing and logistics vocabulary around them. Over 60 terms, each with a one-line definition.

A CoA is a lot-specific record of tests actually performed on the material you are receiving. It is not a datasheet, not a specification, and not a warranty of function. What each line means, the four questions that expose a weak CoA, and what to demand before you order.

DMSO concentration, controlled-rate versus passive freezing, vapour-phase versus liquid-phase nitrogen storage, and thaw technique. What each parameter does mechanistically, what the evidence supports, and what to specify when buying cryopreserved cells.

The three main routes to human neurons in vitro compared on time to maturity, purity, subtype fidelity, cost, network activity and when each is appropriate. NGN2 induction is fast and homogeneous; developmental cortical protocols run around 80 days.

Multielectrode array, manual and automated patch clamp, calcium imaging and voltage indicators measure different physical quantities at different resolutions. What each actually records, throughput and invasiveness, what each cannot see, and how to choose for a specific question.

An engineered living component is a living biological construct produced to a written specification, intended to function as a part within a larger system. Definition, taxonomy, boundary cases, and relation to tissue engineering, biofabrication and synthetic biology.

An isogenic control is a cell line genetically identical to its comparator except at the edited locus. Why unmatched controls make disease-modelling data uninterpretable, how isogenic pairs are generated, and the six things to verify before buying one.

Matrigel is an undefined tumour-derived basement membrane extract; laminin, vitronectin and fibronectin are defined single-protein or recombinant substrates. What each provides, which integrins they engage, where lot-to-lot variability comes from, and how to plan a substrate switch.

MEA-ready is an undefined marketing term for neuron products sold for multielectrode array use. Here is the checklist of seven attributes that actually determine whether a product will produce network activity on an MEA.

Passage number counts subculture events, not cell divisions, and is not comparable between suppliers because split ratios differ. Population doubling level is the transferable unit. How to convert, what senescence thresholds mean, and what to demand on a datasheet.

Post-thaw viability is the percentage of cells in a thawed cryopreserved vial judged alive by a stated assay at a stated time. Method comparison across trypan blue, AO/PI and plating efficiency, and why vendor numbers are not comparable.

RUO cells are supplied for research use only with no regulatory manufacturing standard behind them; GMP cells are manufactured under a quality system for clinical use. Comparison of documentation, testing, price, permitted use, and when RUO is sufficient.

A seed train is the staged expansion from a thawed vial to production scale. What master and working cell banks are under ICH Q5D, why the two-tier structure exists, what expansion capacity actually limits, and what to ask when a supplier quotes a batch.

Sterility testing and mycoplasma testing are separate tests covering different organisms; neither substitutes for the other. The compendial methods, PCR versus culture detection limits, why a negative result is not the same as absence, and what to demand on a CoA.

A complete field checklist for requesting quotes on cells, engineered tissue and custom culture devices, plus a fully worked example RFQ. Written so two suppliers quoting the same document produce comparable numbers.

Nine sourcing categories, with lead time, delivery format, QC scope and quote type for each.

Sourceable entries, with the manufacturer stated on every entry.

Roles, ordering sequence, fee structures and limits.

Submit one specification and receive comparable quotes.

How suppliers are researched, and what each verification label means.

An open file format for describing a living component.

A machine-checkable package compared with a specification PDF.

Check a WWD package against the schema in your browser. Nothing is uploaded.

Reference packages and JSON schemas.

How to comment on the standard and propose changes.

Scope, completed work, operating rules and buyer types.

Where to send a specification, and where to send everything else.

What suppliers are sent, what is expected back, and how to get onto the sourcing list.

Terms, privacy, research-use restriction, export and biosecurity, shipping, confidentiality.